Diagnostic biomarkers to differentiate sepsis from cytokine release syndrome in critically ill children
Chimeric antigen receptor (CAR) T-cells directed against CD19 have drastically altered
outcomes for children with relapsed and refractory acute lymphoblastic leukemia (r/r ALL) …
outcomes for children with relapsed and refractory acute lymphoblastic leukemia (r/r ALL) …
Risk-adapted preemptive tocilizumab decreases severe cytokine release syndrome (CRS) after CTL019 CD19-targeted chimeric antigen receptor (CAR) T-cell …
Background Patients (pts) receiving CTL019 (tisagenlecleucel) for B-ALL with high tumor
burden (HTB) are at high risk for developing severe CRS. Tocilizumab, an IL-6 receptor …
burden (HTB) are at high risk for developing severe CRS. Tocilizumab, an IL-6 receptor …
Identification of predictive biomarkers for cytokine release syndrome after chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia
DT Teachey, SF Lacey, PA Shaw, JJ Melenhorst… - Cancer discovery, 2016 - AACR
Chimeric antigen receptor (CAR)–modified T cells with anti-CD19 specificity are a highly
effective novel immune therapy for relapsed/refractory acute lymphoblastic leukemia …
effective novel immune therapy for relapsed/refractory acute lymphoblastic leukemia …
Prediction of severe CRS and determination of biomarkers in B cell-acute lymphoblastic leukemia treated with CAR-T cells
Z Wei, J Xu, C Zhao, M Zhang, N Xu, L Kang… - Frontiers in …, 2023 - frontiersin.org
Introduction CAR-T cell therapy is a novel approach in the treatment of hematological
tumors. However, it is associated with life-threatening side effects, such as the severe …
tumors. However, it is associated with life-threatening side effects, such as the severe …
Cytokine release syndrome after chimeric antigen receptor T cell therapy for acute lymphoblastic leukemia
JC Fitzgerald, SL Weiss, SL Maude… - Critical care …, 2017 - journals.lww.com
Objective: Initial success with chimeric antigen receptor–modified T cell therapy for
relapsed/refractory acute lymphoblastic leukemia is leading to expanded use through …
relapsed/refractory acute lymphoblastic leukemia is leading to expanded use through …
Comprehensive serum proteome profiling of cytokine release syndrome and immune effector cell–associated neurotoxicity syndrome patients with B-cell all receiving …
Purpose: To study the biology and identify markers of severe cytokine release syndrome
(CRS) and immune effector cell–associated neurotoxicity syndrome (ICANS) in children after …
(CRS) and immune effector cell–associated neurotoxicity syndrome (ICANS) in children after …
Prevalence of systemic inflammatory response syndrome (SIRS) in hospitalized children: a point prevalence study
J Pavare, I Grope, D Gardovska - BMC pediatrics, 2009 - Springer
Background In accordance with the 1st International pediatric sepsis consensus conference,
where sepsis was defined as SIRS associated with suspected or proven infection, we have …
where sepsis was defined as SIRS associated with suspected or proven infection, we have …
Predictive role of endothelial cell activation in cytokine release syndrome after chimeric antigen receptor T cell therapy for acute lymphoblastic leukaemia
F Hong, M Shi, J Cao, Y Wang, Y Gong… - Journal of Cellular …, 2021 - Wiley Online Library
CD19‐target chimeric antigen receptor (CAR)‐T cell therapy is highly effective for
relapsed/refractory (R/R) acute lymphoblastic leukaemia (ALL), but is often complicated by …
relapsed/refractory (R/R) acute lymphoblastic leukaemia (ALL), but is often complicated by …
Cytokine release syndrome grade as a predictive marker for infections in patients with relapsed or refractory B-cell acute lymphoblastic leukemia treated with chimeric …
JH Park, FA Romero, Y Taur, M Sadelain… - Clinical Infectious …, 2018 - academic.oup.com
Background Chimeric antigen receptor (CAR)–modified T cells that target the CD19 antigen
present a novel promising therapy for the treatment of relapsed B-cell acute lymphoblastic …
present a novel promising therapy for the treatment of relapsed B-cell acute lymphoblastic …
Admission chemokine (CC motif) ligand 4 levels predict survival in pediatric septic shock
JE Nowak, DS Wheeler, KK Harmon… - Pediatric Critical Care …, 2010 - journals.lww.com
Objective: Stratification with an effective outcome biomarker could improve the design of
interventional trials in pediatric septic shock. The objective of this study was to test the …
interventional trials in pediatric septic shock. The objective of this study was to test the …